^
    Back
    Association details:
    Biomarker:AR expression
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

    Excerpt:
    ...Percentage of Participants With a >= 50% Decline in Prostate-specific Antigen (PSA) Value`Percentage of Participants With Tumor Protein 53 Gene (TP53) Copy Number Alterations and Mutations`Percentage of Participants With Phosphatase and Tensin Homologue Gene (PTEN) Copy Number Alterations and Mutations`Percentage of Participants With Retinoblastoma Gene (RB1) Copy Number Alterations and Mutations`Androgen Receptor (AR) Messenger RNA (mRNA) Expression`Androgen Receptor Variant 7 (AR-V7) Expression`Percentage of Participants With Androgen Receptor (AR) Copy Number Alterations and Mutations`Number of Participants With Protein Expression of AR`Androgen Receptor (AR) Activity Level...
    Trial ID:
    NCT02099864
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

    Excerpt:
    ...- Expression of AR-V7 is...
    Trial ID:
    NCT03123978
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

    Excerpt:
    ...The change in protein expression of androgen receptor (AR7) splice variant and AR / AR pathway mutations as a mechanism of resistance to abiraterone/enzalutamide is evaluated by measuring the difference in a quantitative immunohistochemical biomarker between assays performed before and after treatment.`...
    Trial ID:
    BARRIER-P
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

    Published date:
    05/18/2020
    Excerpt:
    Levels of AR mRNA and protein expression were also similar between nonresponders and responders (Fig. 4B and SI Appendix, Table S2), suggesting that AR genomic changes or AR expression changes are not good predictors of enzalutamide response.
    DOI:
    https://doi.org/10.1073/pnas.1922207117
    Trial ID:
    NCT02099864